Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 4 of 4 for “"tumor distribution"”.

  1. PRECLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF NEW ANTICANCER AGENTS FOR BRAIN TUMOR CHEMOTHERAPY

    … (GBM) is the most common malignant primary brain tumor in adults for which overall prognosis remains poor despite recent treatment advances, thus emphasizing the need for developing effective therapeutic agents. Styryl sulfones belong to a class of non-ATP competitive antineoplastic agents in …

    temple Repository record for PRECLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF NEW ANTICANCER AGENTS FOR BRAIN TUMOR CHEMOTHERAPY (opens in a new tab)

  2. DEVELOPMENT OF BISPECIFIC T CELL ENGAGERS TARGETING CARBONIC ANHYDRASE 9 FOR THE IMMUNE THERAPY OF CLEAR CELL RENAL CELL CARCINOMA

    … (BTEs) that target T cell cytotoxicity to tumors by simultaneously binding T cell and cancer antigens, for which exist multiple design formats. However, there are limited comparative characterizations among formats for the optimal selection and design of new therapies. Here, we sought to …

    penn Repository record for DEVELOPMENT OF BISPECIFIC T CELL ENGAGERS TARGETING CARBONIC ANHYDRASE 9 FOR THE IMMUNE THERAPY OF CLEAR CELL RENAL CELL CARCINOMA (opens in a new tab)

  3. Development and Intratumoral Distribution of Block Copolymer Micelles as Nanomedicines for the Targeted Delivery of Chemotherapy to Solid Tumors

    … tissues and concentration of the drug within the tumor. As such, encapsulation of chemotherapeutic agents inside nanoparticles capable of enhancing tumor-targeted drug delivery is a particularly promising innovation. Yet, initial investigations into the intratumoral fate of nanomedicines have …

    toronto-retro Repository record for Development and Intratumoral Distribution of Block Copolymer Micelles as Nanomedicines for the Targeted Delivery of Chemotherapy to Solid Tumors (opens in a new tab)

  4. Exploring multivalency and chemical modifications in the development of anti-PD-L1 peptide inhibitors for cancer immunotherapy

    … to drawbacks associated with Abs, such as low tumor penetration, high immunogenicity, and prolonged occupancy of target receptors. Over the past decade, peptides have garnered considerable interest as promising alternatives to address the limitations of existing anti-PD-L1 therapies and to …

    umkc Repository record for Exploring multivalency and chemical modifications in the development of anti-PD-L1 peptide inhibitors for cancer immunotherapy (opens in a new tab)